Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247804 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
- 20
- Study locations
NCT02247804 is a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Allergan. The registered enrollment target is 594 participants, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (122% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02247804, a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Conditions Studied
Interventions
- DRUG Bimatoprost SR
- DRUG Active Comparator: Timolol 0.5%
- OTHER Sham: Applicator Without Needle
- DRUG Timolol Vehicle (placebo)
Study Locations (20)
California
- Lugene Eye Institute - Glendale
- Lakeside Vision Center - Irvine
- Hamilton Glaucoma Center, Shiley Eye Center UCSD - La Jolla
- Atlantis Eye Care - Long Beach
- Glaucoma Institute of Beverly Hills - Los Angeles
- Montebello Medical Eye Center Inc. - Montebello
- Stanford University - Palo Alto
- Foothill Eye Institute - Pasadena
- Martel Eye Medical Group - Rancho Cordova
- Grutzmacher, Lewis and Sierra, Inc. - Sacramento
- Pacific Eye Associates - San Francisco
Florida
- Palm Beach Eye Center, INC - Atlantis
- Nature Coast Clinical Research - Crystal River
- Levenson Eye Associates - Jacksonville
- East Florida Eye Institute - Stuart
- International Research Center - Tampa
Arizona
- Arizona Glaucoma Specialists - Phoenix
Colorado
- Eye Associates of Colorado Springs - Colorado Springs
Georgia
- Coastal Research Associates, LLC - Roswell
Illinois
- Chicago Eye Specialists - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2014-12-15 |
| Est. Completion | 2019-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02247804
The ClinicalTrials.gov registry entry for NCT02247804 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 594 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (122% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Bimatoprost SR is the first listed.
NCT02247804 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02247804 about?
NCT02247804 is a clinical study titled "Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension". This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
What is the current status of trial NCT02247804?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2014-12-15. Estimated completion is 2019-07-19.
What conditions does trial NCT02247804 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT02247804?
The interventions under investigation include: Bimatoprost SR (DRUG), Active Comparator: Timolol 0.5% (DRUG), Sham: Applicator Without Needle (OTHER), Timolol Vehicle (placebo) (DRUG).
Who is sponsoring clinical trial NCT02247804?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02247804 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.